Chen Luyao, Li Hongzhao, Gu Liangyou, Ma Xin, Li Xintao, Zhang Fan, Gao Yu, Fan Yang, Zhang Yu, Xie Yongpeng, Zhang Xu
State Key Laboratory of Kidney Diseases, Department of Urology, Chinese PLA Medical School, Chinese PLA General Hospital, Beijing, People's Republic of China.
Medical School, Nankai University, Tianjin, People's Republic of China.
Sci Rep. 2016 Feb 18;6:21325. doi: 10.1038/srep21325.
The relationship between urinary collecting system invasion (UCSI) and oncological outcomes in renal cell carcinoma (RCC) patients has attracted extensive attention recent years. However, the reports were inconsistent and remain controversial. Thus, we performed a systematic literature search of PubMed, Embase, Web of Science and The Cochrane Library databases to identify relevant studies up to June 2015 and conducted a standard meta-analysis of survival outcomes. 17 studies containing 9012 RCC patients satisfied the inclusion criteria. Pooled HRs for overall survival (OS) and recurrence-free survival (RFS) were 1.45 (95%CI, 1.26-1.66, P < 0.001) and 2.27 (95% CI, 1.54-3.34, P < 0.001), respectively. Further subgroup analysis suggested that UCSI was significant associated with poor cancer-specific survival (CSS) in stage T1-T2 RCC (HR = 2.05, 95%CI: 1.43-2.96, P < 0.001) but not in stage T3-T4 tumors (HR = 1.08, 95%CI: 0.63-1.85, P = 0.771). Current evidence revealed that UCSI has a significant negative impact on OS and RFS in RCC patients and could be used to predict CSS especially in localized RCC. Thus, RCC patients with UCSI should be paid more attention by clinician and pathologist and require close follow up for their poor prognosis.
近年来,肾细胞癌(RCC)患者的泌尿系统侵犯(UCSI)与肿瘤学预后之间的关系引起了广泛关注。然而,相关报道并不一致,仍存在争议。因此,我们对PubMed、Embase、Web of Science和Cochrane图书馆数据库进行了系统的文献检索,以识别截至2015年6月的相关研究,并对生存结果进行了标准的荟萃分析。17项研究共纳入9012例RCC患者,符合纳入标准。总生存(OS)和无复发生存(RFS)的合并风险比(HR)分别为1.45(95%CI,1.26 - 1.66,P < 0.001)和2.27(95%CI,1.54 - 3.34,P < 0.001)。进一步的亚组分析表明,UCSI与T1 - T2期RCC患者较差的癌症特异性生存(CSS)显著相关(HR = 2.05,95%CI:1.43 - 2.96,P < 0.001),但与T3 - T4期肿瘤无关(HR = 1.08,95%CI:0.63 - 1.85,P = 0.771)。目前的证据显示,UCSI对RCC患者的OS和RFS有显著负面影响,尤其在局限性RCC中可用于预测CSS。因此,临床医生和病理学家应更加关注伴有UCSI的RCC患者,鉴于其预后较差,需要密切随访。